"It’s important for us to think about ITP as any other autoimmune disorder. When it’s flaring, fatigue is associated." -- Michelle Sholzberg, MDCM, MSc, St. Michael’s Hospital, Toronto The study, ...
An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...
Several areas of discordance were observed, including contributing causes for delay in diagnosis, with patients perceiving extended wait times as a significant contributing factor. Patients were ...
Basel, June 15, 2018 - Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results ...
STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented results from an online survey highlighting disease ...
Immune thrombocytopenia (ITP) doesn’t have a cure and can be unpredictable. There are two main types of ITP, acute and chronic. The acute type usually lasts six months or less. It’s more common in ...
A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and ...
Improvements in all HRQoL measures from the end of ADVANCE IV were observed in both the efgartigimod treatment or cross-over to efgartigimod groups of the study. Patients with primary immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results